Hikal Share Price

NSE
HIKAL •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Hikal Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
25.33% Fall from 52W High
-14.1
TTM PE Ratio
High in industry
57.4
Price to Book Ratio
Above industry Median
3.6
Dividend yield 1yr %
Above industry Median
0.5
TTM PEG Ratio
PEG TTM is much higher than 1
14

Hikal Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Hikal Quarterly Revenue

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
447.7 Cr
452.9 Cr
406.8 Cr
514.1 Cr
447.57 Cr

Hikal Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
1787.05 Cr
2028.44 Cr
1947.61 Cr
1725.42 Cr
1510.96 Cr

Hikal Quarterly Net Profit/Loss

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
17.2 Cr
18.3 Cr
5.1 Cr
33.97 Cr
16.14 Cr

Hikal Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
69.6 Cr
78.38 Cr
160.5 Cr
133.14 Cr
84.44 Cr
Hikal Result Highlights
  • Hikal Ltd reported a 0.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 0.8%.

  • Its expenses for the quarter were down by 0.2% QoQ and up 0.3% YoY.

  • The net profit decreased 6.0% QoQ and increased 6.6% YoY.

  • The earnings per share (EPS) of Hikal Ltd stood at 1.4 during Q3FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Hikal shareholding Pattern

Promoter
68.8%
Foreign Institutions
6.1%
Mutual Funds
2.9%
Domestic Institutions
3.4%
Public
21.6%
Promoter
68.8%
Foreign Institutions
6.8%
Mutual Funds
3.2%
Domestic Institutions
3.6%
Public
20.8%
Promoter
68.8%
Foreign Institutions
6.7%
Mutual Funds
2.7%
Domestic Institutions
3.1%
Public
21.3%
Promoter
68.8%
Foreign Institutions
6.6%
Mutual Funds
3%
Domestic Institutions
3.5%
Public
21.1%
Promoter
68.8%
Foreign Institutions
6.1%
Mutual Funds
2.7%
Domestic Institutions
3.2%
Public
21.8%
Promoter
68.8%
Foreign Institutions
4.8%
Mutual Funds
2.7%
Domestic Institutions
3.1%
Public
23.2%

Hikal Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
16
5Day EMA
350.90
10Day EMA
354.80
12Day EMA
355.60
20Day EMA
358.60
26Day EMA
361.10
50Day EMA
368.30
100Day EMA
368.70
200Day EMA
355.50
5Day SMA
350.20
10Day SMA
359.30
20Day SMA
355.80
30Day SMA
360.50
50Day SMA
375.10
100Day SMA
377.10
150Day SMA
367.10
200Day SMA
352.60
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
94146 Rs
210615 Rs
Week Rs
104529 Rs
306580 Rs
Month Rs
100839 Rs
279510 Rs
Resistance & Support
343.38
Pivot
Resistance
First Resistance
350.67
Second Resistance
359.58
Third Resistance
366.87
Support
First Support
334.47
Second support
327.18
Third Support
318.27
Relative Strength Index
41.71
Money Flow Index
60.72
MACD
-5.53
MACD Signal
-5.29
Average True Range
17.55
Average Directional Index
22.36
Rate of Change (21)
-7.43
Rate of Change (125)
6.03

Hikal Company background

Founded in: 1988
Managing director: Sameer Hiremath
Hikal Limited, incorporated on July 08th, 1988, has emerged as one of the preferred partners for global companies in segments such as pharmaceuticals, crop protection, animal health, biocides, and specialty chemicals. The Company is engaged in the manufacturing of various chemical intermediates, specialty chemicals, active pharma ingredients and contract research activities. Presently, it is operating in the crop protection and pharmaceuticals space.The Company has 5 manufacturing facilities across three states in India. It supply products to customers across the globe in the US, Japan, Europe, Canada, South East Asia, LATAM, India and RoW. Apart from this, it specialize in manufacturing APIs and intermediates in pharmaceutical division. Within pharmaceutical division, it offer human health and animal health products.Hikal commenced its first project in 1991 at its first greenfield site at M.I.D.C., Mahad with the manufacture of intermediates for agrochemical industry. It also bagged first big contract with Hoechst. During 1996, Company came with public issue to part finance the expansion project of Thiabendazol. It achieved another milestone when Merck Co., USA chose Hikal as a partner to outsource Thiabendazole (TBZ, a fungicide). Since the capacity at Mahad was inadequate, Hikal built second greenfield site, a stateoftheart manufacturing facility at Taloja in 1997. The Company has been accorded Export House status by the Government of India. It set up a new manufacturing facility near Mumbai in collaboration with Merck Co Inc, USA, for the manufacture of a postharvest fungicide. It received the prestigious 5 star Safety Award from British Safety Council UK for high standards maintained at the Taloja Site.During 19992000, the company has acquired an Agrochemical manufacturing site at Panoli, Gujarat from Novartis India Limited. The Companys status as an Export House has been elevated to that of a Trading House. In 2001, it entered the pharmaceuticals business, when it acquired the RD Unit and Bulk Drug Manufacturing Facility of Wintac Ltd at Bangalore in Karnataka. In 2004, it built a brand new API plant postacquisition and received USFDA certification. The Bangalore API Plant approved by USFDA and Australian TGA. During 200405, A 100% EOU plant for pharamaceutical intermediates is being set up. This unit is expected to be operational in the first half of the coming year. During 200405, the company is establishing a stateoftheart RD facility in Pune and this research facility is expected to be operational in early 2006.In Aug. 2004, the company has entered into an agreement with Bayer CropScience AG to manufacture and supply Agro biochemical intermediates and has set up a plant to manufacture this products in Mahad Plant. In 2005, the company made an agreement with Crompton Corporation, USA to manufacture and market a New Generation Crop protection product. In Nov. 2005, the company entered into a JV agreement with a subsidiary company of Sinochem Corporation, China.During 20052006, the company made a strategic investment in Jiangsu Chemstar Industries Co (a subsidiary company of Sinochem Corporation China A Fortune 500 company). The company acquired 10% stake in the year. The companies production capacity of Crop protection products and Pharmaceutical products stood at 4436 MTn and 180 MT respectively. The Company commenced export of Gabapentine to the US and Canada markets during FY 200607. It acquired Marsing Co. A/S, Denmark and commenced marketing and distribution of APIs in various countries. The Company increased investment to 16% in Jiangsu Chemstar Industries Co. Ltd., (a subsidiary company of Sinochem Corporation, China A FORTUNE 500 company) in FY2007. During the year, it started supply of new Crop Protection product to one of the leading multinational companies. In Pharma plant, its existing Intermediate products registered increase in volumes and two new Pharma products were manufactured at Panoli site. RD unit labs got upgraded and two new labs were added during the year 200708.In 2008, the Company established Acoris Research Ltd., a contract research facility at the International Biotech Park, Pune, which is fully operational. In 2009, it expanded manufacturing capabilities. Construction of the new multipurpose active ingredients plant for crop protection at the Taloja site was completed. It commissioned several new multipurpose API plants at the US FDA approved site in Bangalore. It commissioned a new multipurpose pharma intermediates plant at Panoli. Longterm contracts with global life sciences companies had a substantial impact on business. It signed longterm contract for a patented molecule with a leading multinational company.As per the Scheme of Arrangement effective from 1st April 2012, the Research and Development activity of Acoris demerged with Hika. Acoris formerly a subsidiary is now a division of Hikal and further strengthened its capabilities, both in terms of manpower as well as technical capabilities.During the year 2013, it signed a manufacturing agreement with a specialty US based food ingredient company. It completed initial supplies for advanced intermediates to one of the largest U.S. biotech companies. It signed a contract with a leading Japanese company to develop different peptides using their proprietary technology. In December 2016, Company sold its stake in subsidiary, Hikal International B.V. In 2017, it sold the RD unit in Bangalore. The Company issued Bonus Shares on 26 June 2018 in the ratio of 1:2 i.e. one bonus equity share of Rs. 2/ each fully paidup for every two existing equity shares of Rs. 2/ each fully paidup held by the members.In 2023, new product launches in the antidiabetic therapeutic area gained significant traction among global customers. The Company made significant progress on the multiyear Animal Health project with a leading global innovator on developing product portfolio.
Read More

Hikal FAQs

Hikal Ltd share price is ₹347.05 in NSE and ₹346 in BSE as on 14/2/2025 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

Hikal Ltd share price in the past 1-year return was 20.58. The Hikal Ltd share hit a 1-year low of Rs. 260.3 and a 1-year high of Rs. 464.75.

The market cap of Hikal Ltd is Rs. 4213.8 Cr. as of 14/2/2025 12:00:00 AM.

The PE ratios of Hikal Ltd is 56.66 as of 14/2/2025 12:00:00 AM.

The PB ratios of Hikal Ltd is 3.5 as of 14/2/2025 12:00:00 AM

The Mutual Fund Shareholding in Hikal Ltd was 2.92% at the end of 14/2/2025 12:00:00 AM.

You can easily buy Hikal Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -